Ani Pharmaceuticals (ANIP) Net Income towards Common Stockholders (QoQ) (2011 - 2026)
Powered by 
Analysis
Ani Pharmaceuticals (ANIP) Net Income towards Common Stockholders (QoQ) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.26% |
| Mar 31, 2026 | 7.28% |
| Dec 31, 2025 | 4.63% |
| Sep 30, 2025 | 222.68% |
| Jun 30, 2025 | -46.70% |
| Mar 31, 2025 | 243.00% |
| Dec 31, 2024 | 56.53% |
| Sep 30, 2024 | -812.10% |
| Jun 30, 2024 | -115.13% |
| Mar 31, 2024 | 2,276.64% |
| Dec 31, 2023 | -92.14% |
| Sep 30, 2023 | 63.31% |
| Jun 30, 2023 | 465.15% |
| Mar 31, 2023 | 122.22% |
| Dec 31, 2022 | 48.37% |
| Sep 30, 2022 | 41.25% |
| Jun 30, 2022 | 25.35% |
| Mar 31, 2022 | 15.58% |
| Dec 31, 2021 | -447.02% |
| Sep 30, 2021 | 68.47% |